AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the ...

Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design ...

Absci (NASDAQ:ABSI – Free Report) had its price objective cut by KeyCorp from $6.00 to $5.00 in a research note released on Wednesday,Benzinga reports. They currently have an overweight rating on the ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Investing.com -- Shares of Absci Corporation (NASDAQ: ABSI) soared 50% following the announcement of a strategic ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration ...

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report) and keeping the price target at ...

KeyBanc lowered the firm’s price target on Absci (ABSI) to $5 from $6 and keeps an Overweight rating on the shares. The firm notes healthcare ...

Absci (ABSI) was rising after a media report on a $20M investment by the semiconductor company Advanced Micro Devices (AMD) in the AI drug creation company.

AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...